249
Participants
Start Date
March 31, 2012
Primary Completion Date
January 31, 2019
Study Completion Date
January 31, 2019
Exenatide
Subjects will inject 5mcg of exenatide subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
Placebo
Subjects will inject 5mcg of identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
Dietary counseling
All subjects will also receive individualized dietary counseling. Subjects in the placebo group will be counseled to follow a hypocaloric diet.
Beth Israel Deaconess Medical Center, Boston
Collaborators (1)
AstraZeneca
INDUSTRY
Jody Dushay
OTHER